Stocks · News reference
Valion Bio To Carry Out Study At Sheba Medical Center To Mull Entolimod In 10 Cancer Participants
Valion Bio, Inc. (NASDAQ:VBIO) today announced a major clinical development milestone with the finalization of an clinical trial protocol at Sheba Medical Center, one of the world's leading hospitals, to evaluate
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 20, 2026, 5:35 PM
- Checked
- Jul 20, 2026, 5:35 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Valion Bio Announces 1-For-25 Reverse Stock Split, Effective Aug. 31
Valion Bio, Inc. (Nasdaq:VBIO) ("Valion Bio" or the "Company) announced today that its Board of Directors has declared a 1-for-25 reverse stock split of the Company's issued and outstanding shares of
Read original at benzinga8-K filing — Valion Bio, Inc. (VBIO)
Filed: 2026-08-27 AccNo: 0001683168-26-006742 Size: 244 KB Item 3.03: Material Modifications to Rights of Security Holders Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarWhy Cadeler Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Shares of Cadeler A/S (NYSE: CDLR) surged in pre-market trading after reporting strong financial results for the first half of 2026. Revenue and profit increased significantly, and full-year guidance was maintained. Other stocks also moved in pre-market trading.
Read original at benzinga